Lenalidomide promotes the development of <i>TP53</i>-mutated therapy-related myeloid neoplasmsAdam S. Sperling, Koichi Takahashi, Veronica Guerra et al.|Blood|2022Cited by 138
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 InhibitorsAhmad S. Alotaibi, Naval Daver, Gautam Borthakur et al.|Blood Cancer Discovery|2020Cited by 97
Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)Veronica Guerra, Koichi Takahashi, Yuanqing Yan et al.|Blood|2019Cited by 8